First Epoetin Alfa Biosimilar Approved in the US

Share this post

The first biosimilar erythropoiesis-stimulating agent has received FDA approval for a number of indications. It is expected to be less costly than the patented biologic.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply